For the first time, our study highlights that all EBVaGC cases exhibit intact CDKN2A, a stark contrast to nasopharyngeal cancer (NPC), where over 30% of cases show CDKN2A deletion, particularly in EBV‐positive instances. The gene discussed is CDKN2A; the disease is nasopharyngeal carcinoma.